CYTKCytokinetics, Incorporated

1. Aug 28, 2026On August 28, 2026, Cytokinetics, Incorporated issued a press release announcing its presentation of the full results of ACACIA-HCM at the European Society of Cardiology (ESC) Congress 2026 and published in the New England Journal of Medicine.Other event · Form 8-K
2. Aug 13, 2026On August 13, 2026, Cytokinetics, Incorporated (the “Company”) filed a complaint in the United States District Court for the District of Delaware against Bristol-Myers Squibb Company and MyoKardia, Inc. The complaint seeks a declaratory judgment that the Company does not infringe U.S. Patent No. 12,616,697 (the “’697 …Other event · Form 8-K
3. Aug 6, 2026Cytokinetics Reports Second Quarter 2026 Financial Results and Provides Business Update.Earnings release · press release
4. May 8, 2026Underwriting Agreement On May 6, 2026, Cytokinetics, Incorporated (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Morgan Stanley & Co. LLC, Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC and Jefferies LLC, as representatives of the several underwriters named therein …Other event · Form 8-K
5. May 5, 2026Forward-Looking Statements This presentation contains forward-looking.Other event · press release
6. May 5, 2026Cytokinetics Reports First Quarter 2026 Financial Results and Provides Business Update.Earnings release · press release
7. Feb 24, 2026Cytokinetics Reports Fourth Quarter 2025 Financial Results and Provides Business Update.Earnings release · press release
8. Feb 17, 2026Cytokinetics, Incorporated today announced that the European Commission has approved MYQORZO® (aficamten), 5 mg, 10 mg, 15 mg and 20 mg tablets for the treatment of symptomatic (New York Heart Association, NYHA, class II-III) obstructive hypertrophic cardiomyopathy in adult patients.Other event · Form 8-K
9. Dec 19, 2025On December 19, 2025, Cytokinetics, Incorporated announced that the U.S. Food and Drug Administration ("FDA") has approved MYQORZO™ (aficamten), 5 mg, 10 mg, 15 mg, 20 mg tablets, for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy ("oHCM") to improve functional capacity and symptoms.Other event · Form 8-K
10. Dec 12, 2025On December 12, 2025, Cytokinetics, Incorporated ("Cytokinetics" or the "Company") announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion recommending marketing authorization in the European Union for MYQORZO® (aficamten), a cardiac myosin …Other event · Form 8-K
11. Nov 14, 2025On November 13, 2025, Cytokinetics, Incorporated (the “Company”) entered into an employment offer letter (the “Offer Letter”) with Jeffrey J. Hessekiel, pursuant to which Mr. Hessekiel has agreed to serve as the Company’s Executive Vice President, Chief Legal and Administrative Officer, effective as of November 14 …Director or officer change · Form 8-K

Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.